Brokerages expect Alder Biopharmaceuticals Inc (NASDAQ:ALDR) to report ($1.13) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Alder Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.99) and the lowest estimate coming in at ($1.36). Alder Biopharmaceuticals reported earnings of ($0.92) per share during the same quarter last year, which indicates a negative year over year growth rate of 22.8%. The business is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Alder Biopharmaceuticals will report full-year earnings of ($4.73) per share for the current fiscal year, with EPS estimates ranging from ($5.50) to ($4.09). For the next fiscal year, analysts forecast that the business will report earnings of ($3.59) per share, with EPS estimates ranging from ($5.46) to ($2.50). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Alder Biopharmaceuticals.

Alder Biopharmaceuticals (NASDAQ:ALDR) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.01.

A number of brokerages have weighed in on ALDR. BidaskClub cut Alder Biopharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. ValuEngine raised Alder Biopharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, June 28th. Canaccord Genuity reaffirmed a “buy” rating and issued a $20.00 price target on shares of Alder Biopharmaceuticals in a research report on Wednesday, June 13th. Mizuho reaffirmed a “buy” rating and issued a $29.00 price target on shares of Alder Biopharmaceuticals in a research report on Thursday, June 7th. Finally, Zacks Investment Research raised Alder Biopharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 10th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and eleven have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $23.33.

In other news, insider John A. Latham sold 24,999 shares of Alder Biopharmaceuticals stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $15.48, for a total value of $386,984.52. Following the transaction, the insider now directly owns 268,692 shares in the company, valued at $4,159,352.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Jeffrey T. L. Smith sold 5,040 shares of Alder Biopharmaceuticals stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $18.00, for a total value of $90,720.00. Following the completion of the transaction, the director now owns 5,871 shares in the company, valued at $105,678. The disclosure for this sale can be found here. Insiders sold 97,238 shares of company stock worth $1,703,022 over the last quarter. 17.40% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. Flinton Capital Management LLC bought a new position in Alder Biopharmaceuticals during the first quarter valued at about $100,000. SG Americas Securities LLC bought a new position in Alder Biopharmaceuticals during the second quarter valued at about $107,000. Neuburgh Advisers LLC bought a new position in Alder Biopharmaceuticals during the first quarter valued at about $121,000. Tower Research Capital LLC TRC bought a new position in Alder Biopharmaceuticals during the second quarter valued at about $128,000. Finally, Xact Kapitalforvaltning AB bought a new position in Alder Biopharmaceuticals during the first quarter valued at about $142,000.

Shares of NASDAQ:ALDR traded up $0.15 on Tuesday, reaching $16.90. The company had a trading volume of 578,200 shares, compared to its average volume of 1,230,503. Alder Biopharmaceuticals has a twelve month low of $9.55 and a twelve month high of $20.87. The stock has a market capitalization of $1.10 billion, a P/E ratio of -3.41 and a beta of 2.59. The company has a debt-to-equity ratio of 0.73, a current ratio of 10.88 and a quick ratio of 10.88.

About Alder Biopharmaceuticals

Alder BioPharmaceuticals, Inc operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions in the United States, Australia, and Ireland.

Read More: Fundamental Analysis and Individual Investors

Get a free copy of the Zacks research report on Alder Biopharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder Biopharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.